Convalescent Plasma Stocks To Watch
Penny stocks shift in an instant and that could be the case for a few companies this week. Over the weekend, U.S. President Donald Trump announced the emergency authorization of convalescent plasma for COVID-19. At a press briefing that began at 5:30 PM EST, the president discussed a “major therapeutic breakthrough on the China virus”. This referred to President Trump confirming that the FDA has issued emergency use authorization for convalescent plasma.
“The FDA has made the independent determination that the treatment is safe and very effective,” said the U.S. President in his briefing on Sunday night.
Read More
- New to Trading? Learn To Become A Profitable Trader Now! Here’s How
- Looking For Penny Stocks On Robinhood? 3 Pot Companies To Watch
If you’re not up to speed on this breakthrough, let’s dive in a bit more. Convalescent plasma comes from blood of COVID-19 patients that’ve recovered from the virus and built antibodies against it. The use of convalescent plasma involves infusing it into people with COVID-19 in order to prevent the disease.
But there’ve been some concerns raised over this methodology. Drs. Anthony Fauci and Francis Collins that initial data was too weak to base a strong thesis off of. This, in turn saw the U.S. FDA put the treatment on hold. However, a presidential emergency authorization bypasses a lot of the hurdles and President Trump is working toward that. He’s said that “I hear great things about it…that’s all I can tell you,” referring to this method of plasma infusion.
Former FDA chief, Dr. Scott Gotlieb recently commented, “I believe plasma is probably beneficial. It’s probably weakly beneficial in the setting of this treatment. But I think some people wanted to see more rigorous data to ground that decision.”
Regardless of the argument for or against the method, convalescent plasma stocks are likely on the menu at the start of the week. With instances like this, it’s also important to understand that volatility and higher risk can play a role. Hyped up sectors tend to see wild trading especially if the government is involved. Knowing that, will these plasma penny stocks be on your watch list on Monday?
Convalescent Plasma Penny Stocks To Watch: ADMA Biologics Inc.
ADMA Biologics Inc (ADMA Stock Report) hasn’t been much of a stand-out this year. After recovering from the big drop in March, ADMA stock has been relatively flat. Though at the end of July, ADMA jumped aggressively higher following The Wall Street Journal coming out with a report that suggested potential opportunities for plasma collection companies. While the penny stock enjoyed a nice 2-day pop, shares came crashing down shortly after. Last week ADMA stock hit a low of $2.47; a level not seen since May.
Much of the negative sentiment came after the company reported its quarterly results at the start of August. However, even as the stock has dropped, it looks like insiders are buying shares. Between August 10th and 13th, officers and directors of the company purchased shares between $2.87 and $3.07 in the open market. Late last week, most plasma stocks took a hit after the New York Times reported the FDA Emergency Use Authorization approval of blood plasma as a potential COVID-19 treatment was on hold.
Considering the seeds were planted earlier this year, traders have been speculating on convalescent plasma stocks. In the press conferences, the President has even hinted further at this idea. He said, “If you’ve had the virus, if you donate, it would be a terrific thing. We really need donations of the plasma. To those that have had the virus: You’ve gotten through it, and I guess that means you have something very special there.”
Considering the sell-off stemming from a delay last week, will this latest development become a new catalyst for plasma penny stocks?
Convalescent Plasma Penny Stocks To Watch: Sonnet BioTherapeutics Holdings Inc.
If you look for a list of plasma penny stocks online, Sonnet BioTherapeutics Holdings Inc. (SONN Stock Report) might not immediately populate that list. There’s been plenty of fanfare for penny stocks like ADMA as well as other leading plasma stocks trading at higher prices.
As far as Sonnet is concerned, it hasn’t had the greatest year so far. In fact, on Friday it reached a new 52-week low of $2.4 0during the morning session. However, some have considered this not only one of the low float penny stocks to watch but also a plasma stock to watch considering its operations.
Sonnet is an oncology-focused biotechnology company with a platform for innovating biologic drugs of single or bispecific action. The company’s FHAB™ (Fully Human Albumin Binding) technology utilizes a fully human single-chain antibody fragment that binds to and “hitch-hikes” on human serum albumin for transport to target tissues.
Read More
- What Are The Best Penny Stocks To Buy? 4 Names To Know This Week
- How Do These Penny Stocks Stack Up? 3 To Watch Next Week
The last time we saw a member of the government mention optimism related to blood plasma, it was at the end of July. In light of this, we also saw SONN stock jump in one of its most active trading days of the year. However, it quickly slid back and continued even lower as you’ll see on the chart. If SONN stock is on your list, be fully aware of the trading history of this penny stock.
Convalescent Plasma Penny Stocks To Watch: T2 Biosystems Inc.
T2 Biosystems Inc. (TTOO Stock Report) is another one of the penny stocks to watch. It has also gotten folded into the mix of convalescent plasma penny stocks to watch. Many of you might be familiar with T2 as we’ve been covering it since late-March. At the time, the company had just reported that Hackensack Meridian Health announced that a rapid test for COVID-19 created by its labs was licensed to T2 Biosystems. Hackensack Meridian is New Jersey’s largest and most comprehensive health network. T2 adapted the coronavirus test to run on its T2Dx® Instrument.
Specifically, the FDA-cleared and CE-marked T2Dx® as a diagnostic system capable of running tests directly from whole blood. At the start of June, anticipation was building around the expected first shipment of the company’s SARS-CoV-2 test. Following that, T2 announced the U.S. launch of the T2SARS-CoV-2™ Panel. In its most recent earnings update, the company gave the outlook for the rest of 2020. Specifically, T2 expects full-year 2020 total revenues of between $18.0 million to $20.0 million. Furthermore, in the U.S., the company expects 60 T2Dx Instrument sales contracts received in 2020.
John Sperzel, President and CEO of T2 Biosystems said, “The strong initial demand from U.S. hospitals for our T2SARS-CoV-2 Panel and T2Dx Instrument, coupled with the susceptibility of critically-ill COVID-19 patients to develop bacterial or fungal co-infections and secondary infections that can lead to sepsis, validates our decision to develop the T2SARS-CoV-2 Panel and we believe will provide an opportunity to drive utilization of our sepsis-related portfolio.”
